首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1457948

全球非藥物測試 (LDT) 市場：市場規模和佔有率分析（依類型、應用和最終用戶）、工業需求預測（截至 2030 年）

Laboratory Developed Tests Market Size and Share Analysis by Type, Application, End User - Global Industry Demand Forecast to 2030

出版日期: 2024年02月01日 | 出版商:

Prescient & Strategic Intelligence | 英文 320 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年全球非藥物檢測（LDT）市場規模將達103.758億美元，2030年將達165.399億美元，複合年增長率為7.2%。該行業的成長很大程度上歸因於癌症和遺傳疾病的增加。

此外，這種增長是由對體外實驗室開發的測試的需求增加所推動的，而目前業界尚無法用於罕見疾病。

分子診斷品類引領產業

到2023年，分子診斷類別將以40%的佔有率引領產業，預計未來幾年將持續下去。其背景是社會老化以及對疾病早期發現的需求日益增長。

癌症類別佔據最大市場佔有率

從應用來看，由於對癌症早期檢測的尖端分子診斷方法的需求不斷增加，癌症類別以 20% 的佔有率領先於該行業。癌症是第二大死因。

北美地區為主要收入來源

北美在 2023 年以約 40% 的佔有率引領產業，預計未來幾年將繼續呈現強勁成長。這是由於該地區擁有先進的實驗室基礎設施和熟練的工作人員。

本報告分析了全球未批准藥物檢測（LDT）市場，並提供了市場的基本結構和最新情況、主要促進和抑制因素以及全球、依地區和主要國家的市場規模前景的資訊（數量）。基礎，2017-2030），依類型、應用和最終用戶劃分的詳細趨勢、當前市場競爭狀況以及主要公司概況。

概述
市場規模：依類型劃分（2017-2030）
市場收入：依類型分類（2017-2030）
市場規模：依應用劃分（2017-2030）
市場收入：依應用分類（2017-2030）
市場規模：依最終用戶劃分（2017-2030）
市場收入：依最終用戶分類（2017-2030）
市場規模：依地區劃分（2017-2030）
市場收入：依地區（2017-2030）

第七章北美市場

概述
市場規模：依類型劃分（2017-2030）
市場收入：依類型分類（2017-2030）
市場規模：依應用劃分（2017-2030）
市場收入：依應用分類（2017-2030）
市場規模：依最終用戶劃分（2017-2030）
市場收入：依最終用戶分類（2017-2030）
市場規模：依國家劃分（2017-2030）
市場收入：依國家分類（2017-2030）

第八章歐洲市場

第九章亞太市場

第十章拉丁美洲市場

第十一章中東和非洲（MEA）市場

第十二章美國市場

概述
市場規模：依類型劃分（2017-2030）
市場收入：依類型分類（2017-2030）
市場規模：依應用劃分（2017-2030）
市場收入：依應用分類（2017-2030）
市場規模：依最終用戶劃分（2017-2030）
市場收入：依最終用戶分類（2017-2030）

第十三章加拿大市場

第十四章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第28章阿拉伯聯合大公國（UAE）市場

第29章競爭格局

市場參與者及其提供的產品/服務的列表
主要企業競爭基準
主要公司的產品基準
近期策略發展狀況

第三十章公司簡介

Quest Diagnostics Incorporated
Abbott Laboratories
Illumina Inc.
F. Hoffmann-La Roche Ltd.
Siemens AG
Bio-Rad Laboratories Inc.
NeoGenomics Laboratories Inc.
Guardant Health Inc.
Becton, Dickinson and Company
QIAGEN N.V.

第31章附錄

簡介目錄

Product Code: 12874

The laboratory-developed tests market had a value of USD 10,375.8 million in 2023, which will power at a compound annual growth rate of 7.2%, to reach USD 16,539.9 million by 2030. The development of this industry is mostly powered by the increase in the occurrence of cancer and genetic ailments.

Furthermore, the growth is credited to the growing requirement for in vitro laboratory-developed tests, currently not available in the industry for rare ailments.

Growth Drivers

The rise in the funding for research and clinical diagnosis of rare diseases and disorders, for example, hematology testing, by a lot of regulatory authorities and the government, powers the industry.

Moreover, these tests are available at lower cost and can aid in developing a wide range of diagnostic tools for various health conditions.

Also, because of the progression in and microarrays, mass spectrometry, lab-developed tests have evolved since complete authority was given to the FDA to control all the instruments for in vitro diagnoses in the year 1976.

Some LDTs are now numerous times more intricate, accessible across the country, able to notice the risk of breast cancer and Alzheimer's disease; and a lot of other IVD tests, which are under premarket review.

The pandemic has also powered the requirement for these tests because of the massive increase in the count of persons screened at public places and health centers.

Molecular Diagnostics Category Leads the Industry

The molecular diagnostic category led the industry with a 40% share in 2023, and this will continue in the years to come as well. This is because of the development of the aging populace and a growth in the requirement for early disease detection.

The increase in the occurrence of infectious and chronic diseases and the surge in the requirement to control healthcare spending are also fueling the growth, by improving the requirement for early diagnosis of the disease and regular monitoring.

Furthermore, the rising acceptance of molecular diagnostics for examining biological markers in the proteome and genome and cell detection expressions makes the category dominant.

Oncology Category Accounted for Largest Share

On the basis of application, the oncology category leads the industry with a 20% share, because of the growing requirement for tech-advanced molecular diagnosis approaches for the early discovery of cancers. Cancer is the second major cause of death.

So, the growing R&D expenditure in oncology would surge the use of enhanced tests.

Moreover, the enhancements in the healthcare infra of developing nations have led to a large share of the category.

North America Generates the Major Revenue

North America leads the industry, with a share of about 40%, in 2023, and it will power at a robust rate in the years to come as well. This will be attributable to the advanced lab infra and availability of skilled staff in the region.

Furthermore, the elevating menace of ailments in the region, the existence of trustworthy healthcare businesses, and strong support for the setup of novel research and development facilities bode well for the industry.

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by type
- 1.4.2. Market size breakdown, by application
- 1.4.3. Market size breakdown, by end user
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
1.5. Market Data Reporting Unit
- 1.5.1. Volume
- 1.5.2. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview
6.2. Market Volume, by Type (2017-2030)
6.3. Market Revenue, by Type (2017-2030)
6.4. Market Volume, by Application (2017-2030)
6.5. Market Revenue, by Application (2017-2030)
6.6. Market Volume, by End User (2017-2030)
6.7. Market Revenue, by End User (2017-2030)
6.8. Market Volume, by Region (2017-2030)
6.9. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

7.1. Overview
7.2. Market Volume, by Type (2017-2030)
7.3. Market Revenue, by Type (2017-2030)
7.4. Market Volume, by Application (2017-2030)
7.5. Market Revenue, by Application (2017-2030)
7.6. Market Volume, by End User (2017-2030)
7.7. Market Revenue, by End User (2017-2030)
7.8. Market Volume, by Country (2017-2030)
7.9. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

8.1. Overview
8.2. Market Volume, by Type (2017-2030)
8.3. Market Revenue, by Type (2017-2030)
8.4. Market Volume, by Application (2017-2030)
8.5. Market Revenue, by Application (2017-2030)
8.6. Market Volume, by End User (2017-2030)
8.7. Market Revenue, by End User (2017-2030)
8.8. Market Volume, by Country (2017-2030)
8.9. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

9.1. Overview
9.2. Market Volume, by Type (2017-2030)
9.3. Market Revenue, by Type (2017-2030)
9.4. Market Volume, by Application (2017-2030)
9.5. Market Revenue, by Application (2017-2030)
9.6. Market Volume, by End User (2017-2030)
9.7. Market Revenue, by End User (2017-2030)
9.8. Market Volume, by Country (2017-2030)
9.9. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

10.1. Overview
10.2. Market Volume, by Type (2017-2030)
10.3. Market Revenue, by Type (2017-2030)
10.4. Market Volume, by Application (2017-2030)
10.5. Market Revenue, by Application (2017-2030)
10.6. Market Volume, by End User (2017-2030)
10.7. Market Revenue, by End User (2017-2030)
10.8. Market Volume, by Country (2017-2030)
10.9. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

11.1. Overview
11.2. Market Volume, by Type (2017-2030)
11.3. Market Revenue, by Type (2017-2030)
11.4. Market Volume, by Application (2017-2030)
11.5. Market Revenue, by Application (2017-2030)
11.6. Market Volume, by End User (2017-2030)
11.7. Market Revenue, by End User (2017-2030)
11.8. Market Volume, by Country (2017-2030)
11.9. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

12.1. Overview
12.2. Market Volume, by Type (2017-2030)
12.3. Market Revenue, by Type (2017-2030)
12.4. Market Volume, by Application (2017-2030)
12.5. Market Revenue, by Application (2017-2030)
12.6. Market Volume, by End User (2017-2030)
12.7. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

13.1. Overview
13.2. Market Volume, by Type (2017-2030)
13.3. Market Revenue, by Type (2017-2030)
13.4. Market Volume, by Application (2017-2030)
13.5. Market Revenue, by Application (2017-2030)
13.6. Market Volume, by End User (2017-2030)
13.7. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

14.1. Overview
14.2. Market Volume, by Type (2017-2030)
14.3. Market Revenue, by Type (2017-2030)
14.4. Market Volume, by Application (2017-2030)
14.5. Market Revenue, by Application (2017-2030)
14.6. Market Volume, by End User (2017-2030)
14.7. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

15.1. Overview
15.2. Market Volume, by Type (2017-2030)
15.3. Market Revenue, by Type (2017-2030)
15.4. Market Volume, by Application (2017-2030)
15.5. Market Revenue, by Application (2017-2030)
15.6. Market Volume, by End User (2017-2030)
15.7. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

16.1. Overview
16.2. Market Volume, by Type (2017-2030)
16.3. Market Revenue, by Type (2017-2030)
16.4. Market Volume, by Application (2017-2030)
16.5. Market Revenue, by Application (2017-2030)
16.6. Market Volume, by End User (2017-2030)
16.7. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

17.1. Overview
17.2. Market Volume, by Type (2017-2030)
17.3. Market Revenue, by Type (2017-2030)
17.4. Market Volume, by Application (2017-2030)
17.5. Market Revenue, by Application (2017-2030)
17.6. Market Volume, by End User (2017-2030)
17.7. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

18.1. Overview
18.2. Market Volume, by Type (2017-2030)
18.3. Market Revenue, by Type (2017-2030)
18.4. Market Volume, by Application (2017-2030)
18.5. Market Revenue, by Application (2017-2030)
18.6. Market Volume, by End User (2017-2030)
18.7. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

19.1. Overview
19.2. Market Volume, by Type (2017-2030)
19.3. Market Revenue, by Type (2017-2030)
19.4. Market Volume, by Application (2017-2030)
19.5. Market Revenue, by Application (2017-2030)
19.6. Market Volume, by End User (2017-2030)
19.7. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

20.1. Overview
20.2. Market Volume, by Type (2017-2030)
20.3. Market Revenue, by Type (2017-2030)
20.4. Market Volume, by Application (2017-2030)
20.5. Market Revenue, by Application (2017-2030)
20.6. Market Volume, by End User (2017-2030)
20.7. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

21.1. Overview
21.2. Market Volume, by Type (2017-2030)
21.3. Market Revenue, by Type (2017-2030)
21.4. Market Volume, by Application (2017-2030)
21.5. Market Revenue, by Application (2017-2030)
21.6. Market Volume, by End User (2017-2030)
21.7. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

22.1. Overview
22.2. Market Volume, by Type (2017-2030)
22.3. Market Revenue, by Type (2017-2030)
22.4. Market Volume, by Application (2017-2030)
22.5. Market Revenue, by Application (2017-2030)
22.6. Market Volume, by End User (2017-2030)
22.7. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

23.1. Overview
23.2. Market Volume, by Type (2017-2030)
23.3. Market Revenue, by Type (2017-2030)
23.4. Market Volume, by Application (2017-2030)
23.5. Market Revenue, by Application (2017-2030)
23.6. Market Volume, by End User (2017-2030)
23.7. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

24.1. Overview
24.2. Market Volume, by Type (2017-2030)
24.3. Market Revenue, by Type (2017-2030)
24.4. Market Volume, by Application (2017-2030)
24.5. Market Revenue, by Application (2017-2030)
24.6. Market Volume, by End User (2017-2030)
24.7. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

25.1. Overview
25.2. Market Volume, by Type (2017-2030)
25.3. Market Revenue, by Type (2017-2030)
25.4. Market Volume, by Application (2017-2030)
25.5. Market Revenue, by Application (2017-2030)
25.6. Market Volume, by End User (2017-2030)
25.7. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

26.1. Overview
26.2. Market Volume, by Type (2017-2030)
26.3. Market Revenue, by Type (2017-2030)
26.4. Market Volume, by Application (2017-2030)
26.5. Market Revenue, by Application (2017-2030)
26.6. Market Volume, by End User (2017-2030)
26.7. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

27.1. Overview
27.2. Market Volume, by Type (2017-2030)
27.3. Market Revenue, by Type (2017-2030)
27.4. Market Volume, by Application (2017-2030)
27.5. Market Revenue, by Application (2017-2030)
27.6. Market Volume, by End User (2017-2030)
27.7. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

28.1. Overview
28.2. Market Volume, by Type (2017-2030)
28.3. Market Revenue, by Type (2017-2030)
28.4. Market Volume, by Application (2017-2030)
28.5. Market Revenue, by Application (2017-2030)
28.6. Market Volume, by End User (2017-2030)
28.7. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings
29.2. Competitive Benchmarking of Key Players
29.3. Product Benchmarking of Key Players
29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Quest Diagnostics Incorporated
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
30.2. Abbott Laboratories
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
30.3. Illumina Inc.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
30.4. F. Hoffmann-La Roche Ltd.
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
30.5. Siemens AG
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
30.6. Bio-Rad Laboratories Inc.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
30.7. NeoGenomics Laboratories Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
30.8. Guardant Health Inc.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
30.9. Becton, Dickinson and Company
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
30.10. QIAGEN N.V.
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary